Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson
Just four months after scoring its first cancer drug approval in a decade, Sanofi is staying on the oncology offensive.
The French pharma is planning to accelerate the development of potential treatments, partnering with the University of Texas MD Anderson Cancer Center in a five-year collaboration. By combining Sanofi’s pipeline with MD Anderson’s top-notch clinical trial program in oncology, the pair will launch biomarker-driven clinical studies to better understand which drug cocktails can effectively curb cancer progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.